Anemia
OLYMPUS trial shows advantages of roxadustat vs placebo for increasing hemoglobin
WASHINGTON — Results from the phase 3 OLYMPUS trial presented here show the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat significantly increased hemoglobin levels in patients with anemia and chronic kidney disease compared to those treated with placebo.
FDA approves Reblozyl for beta-thalassemia
The FDA today approved luspatercept-aamt to treat anemia in adults with beta-thalassemia who undergo regular red blood cell transfusions.
Anemia linked to adverse outcomes, including increased dialysis risk, for patients with kidney disease
Researchers from Denmark found the presence of anemia was associated with an increased risk for incident dialysis in patients with chronic kidney disease. In addition, for these patients and those already on dialysis, anemia increased risks for hospitalization, mortality and major adverse cardiovascular events.
Researchers share Nobel Prize for discoveries that may improve treatment of cancer, anemia
Three scientists — two from the United States and one from England — the Nobel Prize in Medicine or Physiology for their discoveries of how cells sense and adapt to oxygen availability.
Maternal anemia in early pregnancy tied to ASD, ADHD in offspring
Ferric citrate complex can increase hemoglobin, reduce serum phosphate in advanced CKD
Ferric citrate complex can help increase hemoglobin and reduce serum phosphate in patients with advanced chronic kidney disease, a recently published study shows.
High hemoglobin levels, anemia linked to dementia, Alzheimer’s risk
In the general population, both high and low levels of hemoglobin were linked to a greater long-term risk for dementia, including Alzheimer’s disease, data published in Neurology showed.
Transfusion timing, volume do not affect mortality among African children with severe anemia
Administering 20 mL/kg or 30 mL/kg blood transfusions immediately produced similar clinical outcomes over 6 months among African children with severe anemia compared with a triggered strategy, according to results of two randomized trials published in The New England Journal of Medicine.
Areas of unmet need for patients with MPN
In this video, Jeanne M. Palmer, MD, hematologist and oncologist at the Mayo Clinic, highlighted areas of unmet need for patients with MPNs, including lack of treatment for patients with myelofibrosis-related anemia and patients who failed on ruxolitinib (Jakafi; Incyte).